WO2007053194A2 - Modulation des dysfonctionnements de la barriere cellulaire - Google Patents

Modulation des dysfonctionnements de la barriere cellulaire Download PDF

Info

Publication number
WO2007053194A2
WO2007053194A2 PCT/US2006/021604 US2006021604W WO2007053194A2 WO 2007053194 A2 WO2007053194 A2 WO 2007053194A2 US 2006021604 W US2006021604 W US 2006021604W WO 2007053194 A2 WO2007053194 A2 WO 2007053194A2
Authority
WO
WIPO (PCT)
Prior art keywords
pa
aeruginosa
opioid receptor
cell
opioid
Prior art date
Application number
PCT/US2006/021604
Other languages
English (en)
Other versions
WO2007053194A3 (fr
Inventor
John C. Alverdy
Jonathan Moss
Mark W. Lingen
Patrick A. Singleton
Joe G.N. Garcia
Original Assignee
The University Of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US68756805P priority Critical
Priority to US60/687,568 priority
Priority to US73100905P priority
Priority to US60/731,009 priority
Priority to US60/760,851 priority
Priority to US76085106P priority
Priority to PCT/US2006/007892 priority patent/WO2006096626A2/fr
Priority to USPCT/US2006/07892 priority
Priority claimed from US11/914,984 external-priority patent/US20080194611A1/en
Application filed by The University Of Chicago filed Critical The University Of Chicago
Publication of WO2007053194A2 publication Critical patent/WO2007053194A2/fr
Publication of WO2007053194A3 publication Critical patent/WO2007053194A3/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine

Abstract

L'invention concerne des procédés prophylactiques et thérapeutiques d'administration d'un antagoniste des récepteurs des µ-opioïdes pour traiter les maladies et les affections de la barrière cellulaire, par exemple les maladies et les affections de la barrière des cellules endothéliales et des cellules épithéliales. Les maladies ou affections concernés par les procédés sont l'inflammation, par exemple les lésions aiguës des poumons, l'athérosclérose, la septicémie d'origine viscérale, les lésions par brûlure, l'entérocolite nécrotique néonatale, la neutropénie grave, la colite toxique, les maladies inflammatoires des viscères, l'entéropathie, le rejet des transplants, la pouchite, l'entérite nécrotique, les infections ophtalmiques médiées par Pseudomonas, les infections otologiques médiées par Pseudomonas et les infections cutanées médiées par Pseudomonas. De manière plus générale, les procédés prophylactiques et thérapeutiques concernés peuvent être envisagés pour traiter les affections de la barrière des cellules épithéliales. Les maladies et les affections peuvent être induits par des pathogènes microbiens, notamment des pathogènes bactériens tels que Pseudomonas aeruginosa. L'invention concerne en outre des procédés prophylactiques et thérapeutiques qui inhibent l'expression de la lectine/adhésine PA-I bactérienne et d'inhibition des niveaux d'activité des MvfR bactériens. L'invention concerne également un procédé utilisant un antagoniste des récepteurs des µ-opioïdes pour la fabrication d'un médicament destiné à être utilisé dans les procédés qu'elle décrit.
PCT/US2006/021604 2005-03-07 2006-06-05 Modulation des dysfonctionnements de la barriere cellulaire WO2007053194A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US68756805P true 2005-06-03 2005-06-03
US60/687,568 2005-06-03
US73100905P true 2005-10-28 2005-10-28
US60/731,009 2005-10-28
US76085106P true 2006-01-20 2006-01-20
US60/760,851 2006-01-20
PCT/US2006/007892 WO2006096626A2 (fr) 2005-03-07 2006-03-07 Utilisation d'antagonistes opioides pour l'attenuation de la proliferation et de la migration des cellules endotheliales
USPCT/US2006/07892 2006-03-07

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US11/914,984 US20080194611A1 (en) 2005-06-03 2006-05-06 Modulation of Cell Barrier Dysfunction
JP2008514938A JP2008542395A (ja) 2005-06-03 2006-06-05 細胞バリア機能障害の調整
EP20060844131 EP1901742A2 (fr) 2005-06-03 2006-06-05 Modulation des dysfonctionnements de la barriere cellulaire
AU2006309292A AU2006309292A1 (en) 2005-06-03 2006-06-05 Modulation of cell barrier dysfunction
CA 2609985 CA2609985A1 (fr) 2005-06-03 2006-06-05 Modulation des dysfonctionnements de la barriere cellulaire
US13/483,932 US20120316190A1 (en) 2005-06-03 2012-05-30 Modulation of Cell Barrier Dysfunction
US14/061,331 US20140142133A1 (en) 2005-06-03 2013-10-23 Modulation of cell barrier dysfunction

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/007892 Continuation-In-Part WO2006096626A2 (fr) 2005-03-07 2006-03-07 Utilisation d'antagonistes opioides pour l'attenuation de la proliferation et de la migration des cellules endotheliales

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US91498408A A-371-Of-International 2008-02-14 2008-02-14
US13/483,932 Continuation US20120316190A1 (en) 2005-03-07 2012-05-30 Modulation of Cell Barrier Dysfunction

Publications (2)

Publication Number Publication Date
WO2007053194A2 true WO2007053194A2 (fr) 2007-05-10
WO2007053194A3 WO2007053194A3 (fr) 2007-08-09

Family

ID=38006351

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/021604 WO2007053194A2 (fr) 2005-03-07 2006-06-05 Modulation des dysfonctionnements de la barriere cellulaire

Country Status (3)

Country Link
EP (1) EP1901742A2 (fr)
CA (1) CA2609985A1 (fr)
WO (1) WO2007053194A2 (fr)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007121447A2 (fr) * 2006-04-17 2007-10-25 The University Of Chicago Utilisation d'antagonistes des opioides pour attenuer la proliferation et la migration des cellules endotheliales
EP2012790A2 (fr) * 2006-04-19 2009-01-14 Smith, Jill P. Traitement de maladies inflammatoires et ulcéreuses du côlon à l'aide d'antagonistes opioïdes
WO2009044883A1 (fr) * 2007-10-05 2009-04-09 Toray Industries, Inc. Remède destiné à soulager des troubles cutanés comprenant un dérivé de morphinane ou l'un de ses sels d'addition d'acide acceptables sur le plan pharmacologique en tant que principe actif
WO2010002576A1 (fr) 2008-07-01 2010-01-07 University Of Chicago Particules contenant un antagoniste de récepteur d'opioïde et procédés d'utilisation correspondants
US8003794B2 (en) 2005-05-25 2011-08-23 Progenics Pharmaceuticals, Inc. (S)-N-methylnaltrexone
US8247425B2 (en) 2008-09-30 2012-08-21 Wyeth Peripheral opioid receptor antagonists and uses thereof
US8338446B2 (en) 2007-03-29 2012-12-25 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof
US8343992B2 (en) 2005-05-25 2013-01-01 Progenics Pharmaceuticals, Inc. Synthesis of R-N-methylnaltrexone
US8471022B2 (en) 2008-02-06 2013-06-25 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2′-bis-methylnaltrexone
US8546418B2 (en) 2007-03-29 2013-10-01 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
US8552025B2 (en) 2003-04-08 2013-10-08 Progenics Pharmaceuticals, Inc. Stable methylnaltrexone preparation
US9102680B2 (en) 2007-03-29 2015-08-11 Wyeth Llc Crystal forms of (R)-N-methylnaltrexone bromide and uses thereof
US9314442B2 (en) 2014-03-25 2016-04-19 Leading BioSciences, Inc. Compositions for the treatment of autodigestion
US9504736B2 (en) 2010-09-23 2016-11-29 The Regents Of The University Of California Administration of serine protease inhibitors to the stomach
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662390B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9717725B2 (en) 2005-03-07 2017-08-01 The University Of Chicago Use of opioid antagonists

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8685995B2 (en) 2008-03-21 2014-04-01 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863928A (en) * 1989-01-04 1989-09-05 Baker Cummins Pharmaceuticals, Inc. Method of treatment for arthritic and inflammatory diseases
US6384044B1 (en) * 1999-11-29 2002-05-07 Bernard Bihari Method of treating cancer of the prostate
US20020173466A1 (en) * 1999-03-03 2002-11-21 Crain Stanley M. Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
US20040024006A1 (en) * 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
WO2006132963A2 (fr) * 2005-06-03 2006-12-14 The University Of Chicago Modulation d'interaction de pathogenes microbiens-cellules hotes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863928A (en) * 1989-01-04 1989-09-05 Baker Cummins Pharmaceuticals, Inc. Method of treatment for arthritic and inflammatory diseases
US20040024006A1 (en) * 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
US20020173466A1 (en) * 1999-03-03 2002-11-21 Crain Stanley M. Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
US6384044B1 (en) * 1999-11-29 2002-05-07 Bernard Bihari Method of treating cancer of the prostate
WO2006132963A2 (fr) * 2005-06-03 2006-12-14 The University Of Chicago Modulation d'interaction de pathogenes microbiens-cellules hotes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZAGON I S ET AL: "OPIOID ANTAGONISTS INHIBIT THE GROWTH OF METASTATIC MURINE NEURO BLASTOMA" CANCER LETTERS, vol. 21, no. 1, 1983, pages 89-94, XP009083862 ISSN: 0304-3835 *

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8552025B2 (en) 2003-04-08 2013-10-08 Progenics Pharmaceuticals, Inc. Stable methylnaltrexone preparation
US9669096B2 (en) 2003-04-08 2017-06-06 Progenics Pharmaceuticals, Inc. Stable pharmaceutical formulations of methylnaltrexone
US9717725B2 (en) 2005-03-07 2017-08-01 The University Of Chicago Use of opioid antagonists
US9662390B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9675602B2 (en) 2005-03-07 2017-06-13 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AU2007237943B2 (en) * 2005-03-07 2013-01-31 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8343992B2 (en) 2005-05-25 2013-01-01 Progenics Pharmaceuticals, Inc. Synthesis of R-N-methylnaltrexone
US8916581B2 (en) 2005-05-25 2014-12-23 Progenics Pharmaceuticals, Inc. (S)-N-methylnaltrexone
US8003794B2 (en) 2005-05-25 2011-08-23 Progenics Pharmaceuticals, Inc. (S)-N-methylnaltrexone
US9597327B2 (en) 2005-05-25 2017-03-21 Progenics Pharmaceuticals, Inc. Synthesis of (R)-N-methylnaltrexone
WO2007121447A2 (fr) * 2006-04-17 2007-10-25 The University Of Chicago Utilisation d'antagonistes des opioides pour attenuer la proliferation et la migration des cellules endotheliales
WO2007121447A3 (fr) * 2006-04-17 2008-06-19 Univ Chicago Utilisation d'antagonistes des opioides pour attenuer la proliferation et la migration des cellules endotheliales
EP2012790A4 (fr) * 2006-04-19 2009-07-01 Smith Jill P Traitement de maladies inflammatoires et ulcéreuses du côlon à l'aide d'antagonistes opioïdes
EP2012790A2 (fr) * 2006-04-19 2009-01-14 Smith, Jill P. Traitement de maladies inflammatoires et ulcéreuses du côlon à l'aide d'antagonistes opioïdes
US8853232B2 (en) 2007-03-29 2014-10-07 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof
US8546418B2 (en) 2007-03-29 2013-10-01 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
US8338446B2 (en) 2007-03-29 2012-12-25 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof
US9102680B2 (en) 2007-03-29 2015-08-11 Wyeth Llc Crystal forms of (R)-N-methylnaltrexone bromide and uses thereof
US9879024B2 (en) 2007-03-29 2018-01-30 Progenics Pharmaceuticals., Inc. Crystal forms of (R)-N-methylnaltrexone bromide and uses thereof
US8772310B2 (en) 2007-03-29 2014-07-08 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof
CN101848714A (zh) * 2007-10-05 2010-09-29 东丽株式会社 以吗啡喃衍生物或其药理学上允许的酸加成盐为有效成分的皮肤性状改善治疗药
CN101848714B (zh) 2007-10-05 2014-08-20 东丽株式会社 以吗啡喃衍生物或其药理学上允许的酸加成盐为有效成分的皮肤性状改善治疗药
WO2009044883A1 (fr) * 2007-10-05 2009-04-09 Toray Industries, Inc. Remède destiné à soulager des troubles cutanés comprenant un dérivé de morphinane ou l'un de ses sels d'addition d'acide acceptables sur le plan pharmacologique en tant que principe actif
US8916706B2 (en) 2008-02-06 2014-12-23 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2′-bis-methylnaltrexone
US8471022B2 (en) 2008-02-06 2013-06-25 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2′-bis-methylnaltrexone
WO2010002576A1 (fr) 2008-07-01 2010-01-07 University Of Chicago Particules contenant un antagoniste de récepteur d'opioïde et procédés d'utilisation correspondants
US8822490B2 (en) 2008-09-30 2014-09-02 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof
US9724343B2 (en) 2008-09-30 2017-08-08 Wyeth, Llc Peripheral opioid receptor antagonists and uses thereof
US9492445B2 (en) 2008-09-30 2016-11-15 Wyeth, Llc Peripheral opioid receptor antagonists and uses thereof
US9180125B2 (en) 2008-09-30 2015-11-10 Wyeth, Llc Peripheral opioid receptor antagonists and uses thereof
US8455644B2 (en) 2008-09-30 2013-06-04 Wyeth Peripheral opioid receptor antagonists and uses thereof
US8420663B2 (en) 2008-09-30 2013-04-16 Wyeth Peripheral opioid receptor antagonists and uses thereof
US8247425B2 (en) 2008-09-30 2012-08-21 Wyeth Peripheral opioid receptor antagonists and uses thereof
US9504736B2 (en) 2010-09-23 2016-11-29 The Regents Of The University Of California Administration of serine protease inhibitors to the stomach
US10137100B2 (en) 2010-09-23 2018-11-27 The Regents Of The University Of California Administration of serine protease inhibitors to the stomach
US9775821B2 (en) 2014-03-25 2017-10-03 Leading BioSciences, Inc. Compositions for the treatment of autodigestion
US9314442B2 (en) 2014-03-25 2016-04-19 Leading BioSciences, Inc. Compositions for the treatment of autodigestion

Also Published As

Publication number Publication date
CA2609985A1 (fr) 2007-05-10
EP1901742A2 (fr) 2008-03-26
WO2007053194A3 (fr) 2007-08-09

Similar Documents

Publication Publication Date Title
Morselli et al. Caloric restriction and resveratrol promote longevity through the Sirtuin-1-dependent induction of autophagy
Grant et al. Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors
Buss et al. Beneficial effects of Mammalian target of rapamycin inhibition on left ventricular remodeling after myocardial infarction
Jain et al. Contribution of Porphyromonas gingivalis lipopolysaccharide to periodontitis
CN1980694B (zh) 凝溶胶蛋白治疗感染的用途
US6765010B2 (en) Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects
US9029413B2 (en) Treatment of viral infections by modulation of host cell metabolic pathways
US20010006967A1 (en) Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists
JP6061922B2 (ja) プロテイノパチーの処置方法
Bermudez et al. Current drug therapy and pharmaceutical challenges for Chagas disease
US20060194769A1 (en) Small molecules that reduce fungal growth
JP6199340B2 (ja) Atoh1発現を増強する化合物
Newman et al. Autophagic cell death of human pancreatic tumor cells mediated by oleandrin, a lipid-soluble cardiac glycoside
JP5409650B2 (ja) 抗精神病薬と組み合わせたカンナビノイドの使用
Rose et al. A Ca2+–calmodulin–eEF2K–eEF2 signalling cascade, but not AMPK, contributes to the suppression of skeletal muscle protein synthesis during contractions
CZ20032927A3 (cs) Léčení cukrovky typu 2 inhibitory z dipeptidylpeptidázy IV
WO2002038142A2 (fr) Compositions serotoninergiques et methodes de traitement de la deficience cognitive legere
Khan et al. Inhibition of autophagy rescues palmitic acid-induced necroptosis of endothelial cells
JP2010024253A (ja) 虚血および再灌流損傷を防止する方法
JP2008520584A (ja) 疼痛を治療するための方法と組成物
KR20140035331A (ko) 화학감각 수용체 리간드-기반 요법
Waldinger et al. The selective serotonin re-uptake inhibitors fluvoxamine and paroxetine differ in sexual inhibitory effects after chronic treatment
Menendez et al. Xenohormetic and anti-aging activity of secoiridoid polyphenols present in extra virgin olive oil: a new family of gerosuppressant agents
JP2003532698A (ja) 細菌の増殖および病理発生を調節するための化合物ならびに方法
HU228915B1 (en) Glucopyranosyloxypyrazole derivatives and use thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2006309292

Country of ref document: AU

ENP Entry into the national phase in:

Ref document number: 2609985

Country of ref document: CA

ENP Entry into the national phase in:

Ref document number: 2008514938

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006844131

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11914984

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06844131

Country of ref document: EP

Kind code of ref document: A2